Differentially expressed messenger RNA/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection (pcRPLND) tissue.
Tim NestlerLara KremerMelanie von BrandensteinMaike WittersheimPia PaffenholzSvenja Wagener-RyczekAlexander QuaasMartin HellmichStefan MüllerDavid PfisterMargarete OdenthalAxel HeidenreichPublished in: Cancer (2022)
The proteins and the corresponding genes called AGR2 and KRT19 can differentiate between teratoma and necrosis in remaining tumor masses after chemotherapy in patients who have metastasized testicular cancer. This may be a way to improve presurgical diagnostics and to reduce the current overtreatment of patients with necrosis only, who could be treated sufficiently by surveillance.
Keyphrases
- newly diagnosed
- end stage renal disease
- ejection fraction
- public health
- papillary thyroid
- robot assisted
- prognostic factors
- lymph node
- peritoneal dialysis
- rectal cancer
- genome wide
- prostate cancer
- young adults
- magnetic resonance
- gene expression
- computed tomography
- sentinel lymph node
- transcription factor
- lymph node metastasis
- nucleic acid
- neoadjuvant chemotherapy
- fine needle aspiration
- childhood cancer